Amgen Inc. $AMGN Shares Bought by Empowered Funds LLC

Empowered Funds LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 26.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 102,898 shares of the medical research company’s stock after purchasing an additional 21,741 shares during the period. Empowered Funds LLC’s holdings in Amgen were worth $28,730,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Brighton Jones LLC raised its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the period. Abel Hall LLC bought a new stake in shares of Amgen during the 1st quarter valued at about $232,000. IFP Advisors Inc raised its stake in Amgen by 13.3% during the first quarter. IFP Advisors Inc now owns 6,911 shares of the medical research company’s stock worth $2,153,000 after acquiring an additional 809 shares during the period. Atlantic Union Bankshares Corp lifted its holdings in Amgen by 1.3% in the first quarter. Atlantic Union Bankshares Corp now owns 4,016 shares of the medical research company’s stock worth $1,251,000 after acquiring an additional 52 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its stake in Amgen by 20.5% in the first quarter. Lindbrook Capital LLC now owns 2,710 shares of the medical research company’s stock valued at $844,000 after acquiring an additional 461 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AMGN. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. Raymond James Financial assumed coverage on Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. DZ Bank raised their target price on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Citigroup upped their price target on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Finally, Scotiabank assumed coverage on shares of Amgen in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $314.05.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 9,036 shares of company stock valued at $2,992,594 over the last quarter. Corporate insiders own 0.76% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $341.71 on Tuesday. Amgen Inc. has a one year low of $253.30 and a one year high of $345.84. The stock’s fifty day moving average is $296.14 and its 200-day moving average is $290.80. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market capitalization of $184.00 billion, a price-to-earnings ratio of 27.94, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.